This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Atreca Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Atreca has a total shareholder equity of $10.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $26.3M and $15.6M respectively.

Belangrijke informatie

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsratio	n/a
Contant	US$21.39m
Aandelen	US$10.76m
Totaal verplichtingen	US$15.58m
Totaal activa	US$26.34m

Recente financiële gezondheidsupdates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: 0C1's short term assets ($24.7M) exceed its short term liabilities ($15.6M).

Langlopende schulden: 0C1 has no long term liabilities.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 0C1 is debt free.

Schuld verminderen: 0C1 has not had any debt for past 5 years.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: 0C1 has less than a year of cash runway based on its current free cash flow.

Voorspelling contante baan: 0C1 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 12.4% each year

This company listing is no longer active

Atreca Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Atreca, Inc. Files Form 15

Atreca, Inc. Receives Written Notification from Nasdaq Regarding Minimum Bid Requirement

Atreca Receives Notice from the Nasdaq Stock Market

Atreca Receives Notice from the Nasdaq Stock Market

Recent updates

Atreca, Inc. Announces Resignation of Franklin Berger from the Board

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Atreca, Inc. Files Form 15

Atreca, Inc.(OTCPK:BCEL) dropped from S&P TMI Index

Atreca, Inc.(OTCPK:BCEL) dropped from NASDAQ Composite Index

Atreca, Inc. Receives Written Notification from Nasdaq Regarding Minimum Bid Requirement

New major risk - Financial position

Atreca, Inc. Announces Board Resignations

Insufficient new directors

Atreca, Inc. Announces Resignation of Herbert Cross, Chief Financial Officer

Atreca, Inc. Announces Resignation of Herbert Cross, Chief Financial Officer

Atreca Receives Notice from the Nasdaq Stock Market

Atreca Receives Notice from the Nasdaq Stock Market

Atreca, Inc. Reduces its Workforce by Approximately 40%

Atreca, Inc. Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors During Oral Abstract

Insufficient new directors

Atreca, Inc. Announces the Appointment of Philippe Bishop, MD, as Chief Medical Officer

Atreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Index

Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer

Atreca, Inc. Announces Publication in PNAS Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101

Atreca, Inc. Provides an Update on Its Preclinical Pipeline in Oncology

Atreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Growth Index

Chief Scientific Officer has left the company

Atreca, Inc Announces Executive Changes

Chief Business Officer has left the company

New 90-day high: €16.00

New 90-day low: €10.50

New 90-day high: €13.60

New 90-day low - €10.50

New 90-day low - €12.70

Atreca, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven